key: cord-0920237-hkcmjx8u
authors: Francesconi, Paolo; Cantini, Fabrizio; Profili, Francesco; Mannoni, Alessandro; Bellini, Benedetta; Benucci, Maurizio
title: COVID-19 epidemiology in rheumatic diseases in Tuscany: a case control study
date: 2021-01-21
journal: Joint Bone Spine
DOI: 10.1016/j.jbspin.2021.105131
sha: 98a704bfd2233e5a7698ce2644eee079e5ce0b0a
doc_id: 920237
cord_uid: hkcmjx8u

• The different screening methodology to capture cases of SARS-CoV-2 infections in patients with rheumatic diseases may result in a variation in the incidence of COVID-19 compared to the general population; • Study confirms the role of corticosteroids in increasing the risk of SARS-CoV-2 infection in patients with chronic rheumatic diseases (RA, AS, PsA) rather than in while connective tissue diseases; • Patients with chronic rheumatic diseases require careful surveillance through serological tests and confirmations with RT-PCR.

First, given the moderate increase of infection risk associated with conventional synthetic DMARDs biologic DMARDs, do we expect a higher number of COVID-19 cases in patients receiving these drugs? Second, considering the anti-cytokine effect of most therapies, may bDMARDs and csDMARDs be potentially protective against the COVID-19? We performed a case control study, in which cases were represented by symptomatic COVID-19 infections occurred from February to July 2020, with a positive PCR test result compared to the general population, and rheumatic diseases and related therapies were considered as exposures. Patients affected by rheumatic diseases were identified through previous Records of Hospital Discharge (SDO) or payment exemption [1] and were aggregated into two groups: connective tissue disease or chronic rheumatic arthritis Therapies administered in 2019 (two prescriptions spaced at least six months apart) with at least one of the following drug groups a) hydroxychloroquine b) corticosteroids c) immunosuppressants or csDMARD, tsDMARD , bDMARDs were also considered. Odds ratios (with 95% confidence interval) of COVID-19 were performed for each single covariate (type of rheumatic diseases, age band, gender and therapies), crude and adjusted for all the other covariates, by multivariate logistic regression model. All the analyses were performed by using STATA 15. Over a 6-month period, 4.581 COVID-19 symptomatic cases in 2,589,374 Tuscany people older than 30 years were recorded.

Age and gender distribution of the general population and of the COVID-19 cases are shown in Table   1 . As expected, the majority of the COVID-19 cases were observed in older people, with a cumulative 49.8% of cases occurring in the subjects older than 70. Overall, chronic rheumatic arthritis were more frequent among cases than in the general population (OR 1.87), while connective tissue diseases did not. Also, previous use of corticosteroids (OR 2, 13 ) and, to a lesser extent, of csDMARDs (OR 1,52), were more frequent among cases than in the general population, while previous use of hydroxychloroquine and of bDMARDs did not. After the adjustment for age and gender, chronic rheumatic arthritis and previous use of corticosteroids resulted significantly associated with the development of symptomatic COVID-19 (Table-2 ). The epidemiological impact of COVID-19 in J o u r n a l P r e -p r o o f patients with rheumatic diseases being treated with bDMARD has been the subject of several reports by Italian Groups. The methodology for capturing incident cases could have determined different values, with a low incidence using e-mails, telephone calls, survey [2-3-4] . Conversely, a prevalence study or evaluation with serological tests has shown an increased risk in patients with rheumatic diseases [5] [6] . The methodology of our SDO-based study for disease and drug prescription confirms that patients with chronic rheumatic diseases (RA, PsA, AS) have an increased incidence, as observed by a recent Italian registry [7] . The present study confirms the risk association with corticosteroids and the indifferent role of bDMARD and hydroxychloroquine as reported by the Global Rheumatology Alliance Physiscian [8] . Regarding sex and age, we have not observed a gender correlation, while the progression of attendance by age groups 40-49, 50-59, 60-69 years has already been demonstrated in other researches, with a progressive increase in hospitalizations and the demand for intensive care [9] . Furthermore, the epidemiological methodology [10] can determine different results even in a population coming from the same geographic area. This study confirms an increase risk of symptomatic COVID-19 disease associated with chronic rheumatic arthritis and use of corticosteroids but not with connective tissue diseases and use of Hydroxychloroquine, csDMARDs and bDMARDs. 

Ticket payment exemptions for chronic diseases

Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

What is the true incidence of COVID-19 in patients with rheumatic diseases?

COVID-19 Pneumonia in a Large Cohort of Patients Treated With Biological and Targeted Synthetic Antirheumatic Drugs Ann Rheum Dis

Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD

Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy

Italian Registry of the Italian Society for Rheumatology (CONTROL-19). COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19)

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry

Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study

SARS-CoV-2 infection among patients with systemic autoimmune diseases